Morningstar

argenx SE ADR ARGX

Morningstar Rating

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

GlobeNewswire Sep 19, 2024 5:00am
argenx to Present at Upcoming Investor Conferences

GlobeNewswire Aug 28, 2024 5:00am
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

GlobeNewswire Jul 25, 2024 5:00am
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024

GlobeNewswire Jul 18, 2024 5:00am
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

GlobeNewswire Jul 16, 2024 4:30am
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Business Wire Jul 16, 2024 4:15am
Argenx Down Nearly 26%, on Pace for Record Percent Decrease — Data Talk

Global News Select Dec 20, 2023 5:22pm
Argenx stock dives by a third after late-stage trial didn't meet goals

MarketWatch Dec 20, 2023 9:22am
Argenx Down Over 10%, On Track for Largest Percent Decrease Since May 2022 — Data Talk

Global News Select Nov 28, 2023 4:01pm
Argenx Shares Down After Vyvgart Study Misses Primary Endpoint

Global News Select Nov 28, 2023 11:48am

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.